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Abstract
BACKGROUND: Clear cell renal cell carcinoma (CRCC) is the most common malignant tumor of the kidney, and the
clinical outcome of CRCC is relatedwith themetastatic potential of CRCC. A significant proportion ofmetastatic CRCC
remains incurable. Recently, immunotherapy against specific targets such as programmed death 1 (PD1) has been
adapted for fatal cases of CRCC. MATERIALS AND METHODS: In this study, we aimed to evaluate the potential of
tumor-infiltrating PD1-positive lymphocytes or FoxP3-positive regulatory T cells (Tregs) as predictors of the meta-
static potential or prognosis of CRCC and investigate possible correlations with Epstein-Barr virus (EBV) infection in
199 cases of CRCC. RESULTS: PD1 positivity, high Treg number, and EBV infection all predicted poor overall survival
(OS) by univariate analysis. PD1 positivity and high Treg numbers were also significantly correlated with more distant
metastatic relapse (DMR) and poor relapse-free survival (RFS) by univariate analysis. PD1 positivity and high Treg
number were independent prognostic indicators for OS. In addition, PD1 positivity was an independent predictor
of RFS and DMR. EBV infection was an independent predictor of OS of CRCC. CONCLUSION: This study demon-
strates that intratumoral infiltration of PD1-positive or FoxP3-positive lymphocytes can be used as significant prog-
nostic indicators of CRCC and PD1 positivity could be very helpful in the prediction of latent distant metastasis of
CRCCs. Therefore, evaluation of the infiltration of PD-positive cells or Tregs in CRCC may be useful diagnostic tools
for the selection of patients who could benefit from PD1- or Treg-based immunotherapy.
Translational Oncology (2013) 6, 282–289
Introduction
Renal cell carcinoma (RCC) is the most common type of malignant
tumor of the kidney. RCC represents about 3% of human malignant
tumors [1]. Most RCCs are treated by radical nephrectomy [2]. How-
ever, about 20% to 30% of localized RCCs develop latent metastatic
progression after surgical treatment, which is closely correlated with a
fatal course of RCC [3]. The 5-year survival for RCC with metastatic
disease is less than 10% [1,4]. However, RCC is a very unpredictable
tumor for distant metastasis. Therefore, it is important to find the
factors that could predict metastasis of RCC and to explore new treat-
ment modalities for these cases. For the treatment of fatal cases of RCC,
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immunotherapy with interleukin-2 and interferon-α has been adapted.
However, despite intensive immunotherapy trials for advanced RCC,
targeted agents rarely induced complete response [5]. Therefore, there
is a great need for novel therapeutic approaches for advanced RCC; of
these novel approaches, targeted immunotherapy shows great promise
and is an area of active research and increased interest.
Programmed death 1 (PD1) is a member of the CD28 receptor
family and negatively regulates T cell proliferation and function [6,7].
PD1 attenuates immune responses by decreasing induction of various
cytokines [8,9]. Therefore, it is suggested that the presence of PD1-
positive lymphocytes could be involved in the immune evasion of
tumor cells. The infiltration of PD1-positive lymphocytes as a poor
prognostic indicator of human malignant tumors has been suggested
in follicular lymphoma [10] and clear cell RCC (CRCC) [11]. In
CRCC, the infiltration of PD1-positive immune cell was seen in 29%
(77 of 267) of CRCCs and significantly correlated with the progres-
sion of tumor and fatal outcome of CRCC [11]. On the basis of the
prognostic impact of the infiltration of PD1-positive cells in human
cancers, PD1 has been put forth as a novel target of immunotherapy
of RCC [12,13].
Regulatory T cells (Tregs) are a population of immune cells re-
lated with immune suppression [14]. Principally, Tregs are immuno-
suppressive and can inhibit autoimmunity as well as antitumor
responses [14,15]. Treg-mediated immune suppression has been used
in the treatment of autoimmune disease. However, the immuno-
suppressive effects of Treg could result in adverse effects on tumor
biology [16,17]. Because tumor cells also express self-antigen [18],
Treg could be involved in the suppression of antitumor immune re-
sponses [19]. Possibly, Treg-related immunosuppressive function
could be mediated by blocking the function of T cells and antigen-
presenting cells [14,15]. The involvement of Treg in tumor biology
has been suggested by high numbers of Treg in human malignant
tumor. Peripheral blood from RCC patients showed higher numbers
of Treg than healthy individuals [20]. High intratumoral Treg counts
are related to poor prognosis of various human cancers, such as RCC
[20], breast carcinoma [21], gastric carcinoma [17], and diffuse large
B cell lymphoma [22].
Epstein-Barr virus (EBV) is a ubiquitous herpes virus in humans
that is usually apathogenic, yet it is also associated with a number of
malignant diseases, including Burkitt’s lymphoma, nasopharyngeal
carcinoma, and Hodgkin’s lymphoma [23]. EBV infection in RCC is
also highly variable between reports ranging from 6.8% to 89% in dif-
ferent studies [24,25]. Shimakage et al. reported that eight of nine cases
of RCC show EBV expression [25]. In contrast, only 5 of 73 cases
of RCCs showed EBV infection in another report [24]. Interestingly,
the expansion of functional Treg has been reported in EBV-related
human malignant tumors, such as nasopharyngeal carcinoma [26] and
Hodgkin’s lymphoma [27]. In EBV-infected Hodgkin’s lymphoma,
EBV could promote intratumoral migration of Treg by upregulating
chemokine CCL20, resulting in tumor progression [28]. The possibil-
ity that Treg has an important role in the maintenance of EBV latent
infection and that EBV infection induces recruitment of immuno-
suppressive Treg at tumor sites has been suggested [29].
In this study, we evaluated the impact of tumor-infiltrating PD1-
positive lymphocytes for the prediction of distant metastasis and prog-
nosis of CRCC. In addition, because the expression of PD1 in immune
cells is related with the function or expansion of Treg, we also evaluated
the impact of intratumoral Treg on the metastatic potential of CRCC
and its association with EBV infection in CRCCs.
Materials and Methods
Patients and Samples
One hundred ninety-nine cases of CRCC patients diagnosed
between July 1998 and August 2011, for whom initial diagnostic
hematoxylin and eosin–stained slides and paraffin-embedded tissue
blocks were available, were included in the present study. This study
obtained Institutional Review Board approval. Informed consent was
provided according to the Declaration of Helsinki. All of the cases
were reviewed and reclassified according to the criteria of the World
Health Organization Classification [30]. Pathologic staging was re-
viewed on the basis of the tumor, node, and metastasis (TNM) staging
system of the American Joint Committee on Cancer [31]. The patients
were grouped according to their sex, age (<55 vs ≥55), TNM stage
(I vs II, III, and IV), presence of lymph node (LN) metastasis, histologic
nuclear grade (1 vs 2 vs 3 and 4) [32], and histologic tumor necrosis. All
of histologic findings were retrospectively reviewed by two pathologists
without clinicopathologic information.
Immunohistochemical Staining and Scoring
Immunohistochemistry was performed using 3.0-mm tumor cores
for tissue microarray. The tissue cores (one arrayed per case) were ob-
tained from the most solid area of the tumor and were composed pri-
marily of intact tumor cells. The tissue sections were treated with
a microwave antigen retrieval procedure in sodium citrate buffer for
12 minutes. Antibodies for FoxP3 (1:50, clone 236A/E7; eBioscience,
San Diego, CA) and PD1 (1:50, clone NAT; Abcam, Cambridge,
United Kingdom) were used. Immunohistochemical analysis was per-
formed without knowledge of the clinicopathologic information. Each
case was evaluated to quantify the number of tumor-infiltrating FoxP3-
positive Tregs and PD1-positive cells. The number of tumor-infiltrating
FoxP3-positive Tregs and PD1-positive cells was counted at highest
numbered five high-power fields. The counting was performed under
a Nikon ECLIPSE 50i light microscope (Nikon, Tokyo, Japan) with
a ×10 eyepiece with 22-mm field of view (Nikon) and ×40 objec-
tive lens (Plan Flour ×40/0.75; Nikon). The field size was 0.55 mm,
and the area of one high power field (HPF) was 0.238 mm2. Finally,
the total area analyzed per case was 1.188 mm2.
In Situ Hybridization
To determine the localization of EBV in RCCs, we performed EBV-
encoded small RNA (EBER) in situ hybridization using a fluorescein-
conjugated EBV probe for detection of EBER transcripts (NCL-EBV-K;
Novocastra, Newcastle upon Tyne, United Kingdom). The negative
control section was processed identically to the above except that the
EBV probe solution was replaced by a negative control probe solution,
which was provided in the kit. A specimen from a patient with known
EBV-positive nasal NK/T cell lymphoma was used as a positive control.
Because EBER could present in both nuclei and cytoplasm of infected
cells [33], both nuclear and cytoplasmic staining for EBER were con-
sidered as positive staining. EBER in situ hybridization was considered
positive if more than one cell was stained.
Statistical Analysis
After counting the number of FoxP3-positive Tregs and PD1-positive
cells, we classified the patients into low versus high Treg subgroups
and negative versus positive PD1 subgroups. The cutoff numbers for
FoxP3-positive Tregs and PD1-positive cells were determined by receiver
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operating characteristic curve analysis at the highest positive likelihood
ratio point. The cutoff points were nine FoxP3-positive Tregs in five
HPFs and one PD1-positive cell in five HPFs. More than nine Tregs
in five HPFs were included in the high Treg subgroup and more than
one PD1-positive cell in five HPFs were included in the PD1-positive
subgroup. One hundred eleven cases of CRCC were placed in the high
Treg subgroup, and 868 cases were placed in the PD1-positive sub-
group. Pearson chi-squared test, two-sided t test, and one-way analysis
of variance were used to analyze the association between the numbers
of tumor-infiltrating FoxP3-positive Tregs and PD1-positive cells, EBV
infection, and the variable clinicopathologic factors.
The end points of interest were distant metastatic relapse (DMR),
relapse-free survival (RFS), and overall survival (OS). The follow-up
end point was the date of last contact or death through December
2011. OS was measured from the date of diagnosis to the date of death
or last contact. Patients who were alive at last contact were treated as
censored for OS analysis. RFS was calculated as the time from diagnosis
to the date of relapse, death, or last contact. Patients who were alive
at last contact and who did not experience relapse were treated as cen-
sored for RFS analysis. DMR was calculated from the time of diagnosis
to the date of relapse at a distant metastatic site. Patients who were
alive at last contact or died were treated as censored for DMR analysis.
Univariate and multivariate Cox proportional hazards regression analy-
ses were performed to estimate the impact of clinicopathologic factors,
EBV infection, Treg infiltration, and the number of PD1-positive cells
on OS, RFS, and DMR. Kaplan-Meier survival curves were con-
structed to further illustrate the impact of OS and RFS when indicated.
Statistical analysis was performed by using SPSS software (version
18.0). P values less than .05 were considered statistically significant.
Results
Association of PD1-Positive Cells, FoxP3-Positive Tregs, and
EBV Infection with Clinicopathologic Characteristics of CRCC
Immunoreactivity for PD1 was found primarily in the cytoplasm of
the cells (Figure 1, A and B) and FoxP3 was expressed in the nuclei of
the cells (Figure 1, C and D). Positive signals for in situ hybridization
Figure 1. Immunohistochemical staining for FoxP3 and PD1 and in situ hybridization for EBER in CRCC. (A and B) PD1-positive cells
(arrowheads) in the CRCC. (C and D) Cases with low numbers of FoxP3-positive Tregs (C) and high numbers of FoxP3-positive Tregs (D).
Arrows indicate FoxP3-positive Tregs. (E) A positive signal for EBER appears in the nuclei (empty arrowheads) and cytoplasm of tumor
cells. (F) Tumor-infiltrating inflammatory cells also stain positive for EBER. The representative field area of one microscopic image for
PD1 and FoxP3 immunostaining is 0.086 mm2. Original magnification, ×400.
284 PD1 and Treg in Clear Cell RCC Kang et al. Translational Oncology Vol. 6, No. 3, 2013
for EBER were detected in both tumor cells and infiltrating inflamma-
tory cells (Figure 1, E and F). The mean number of PD1-positive cells
in all CRCCs was 18 in 5 HPFs (mean ± SD, 18 ± 46; range, 0–293)
and the mean number of Tregs in all CRCCs was 20 in 5 HPFs
(mean ± SD, 20 ± 32; range, 0–255). EBER positivity was seen in
34% (67/199) of CRCC patients. The PD1-positive subgroup sig-
nificantly correlated with the sex of patients (P = .042), higher clini-
cal stage (P = .003), DMR (P < .001), higher histologic nuclear grade
(P < .001), and the high Treg subgroup (P < .001). The high Treg
subgroup significantly correlated with the sex of patients (P = .005),
higher clinical stage (P = .049), DMR (P = .009), and presence of
histologic tumor necrosis (P = .040). Presence of EBV infection sig-
nificantly correlated only with the presence of histologic tumor necrosis
(P = .032; Table 1).
The Infiltration of PD1-Positive Cells and FoxP3-Positive
Tregs in CRCCs Correlates with Distant Metastatic Relapse,
RFS, and OS according to Univariate Analysis
The factors significantly correlated with DMR, RFS, and OS by uni-
variate analyses were TNM stage and intratumoral infiltration of FoxP3-
positive Tregs or PD1-positive cells (Table 2). In CRCC patients,
intratumoral infiltration of PD1-positive cells predicted shorter DMR
[P = .001; hazard ratio (HR), 12.371; 95% confidence interval (CI),
2.855–53.608], RFS (P < .001; HR, 9.562; 95% CI, 3.729–24.518),
and OS (P < .001; HR, 10.802; 95% CI, 3.259–35.806). High Treg
number in CRCC also predicted shorter DMR (P = .005; HR, 5.776;
95% CI, 1.677–19.895), RFS (P < .001; HR, 5.708; 95% CI, 2.381–
13.687), and OS (P = .001; HR, 6.218; 95% CI, 2.151–17.971).
In addition to the prognostic impact of the infiltration of Tregs and
PD1-positive cells, EBV infection was also significantly associated with
OS (P = .008; HR, 2.792; 95% CI, 1.305–5.977). Kaplan-Meier
survival curves for the impact on OS and RFS of CRCC patients are
shown in Figure 2.
When we evaluated the prognostic significance of the combined
infiltrative pattern of PD1-positive lymphocytes and FoxP3-positive
Tregs (PD1/Treg pattern), the PD1/Treg pattern significantly corre-
lated with DMR (log rank, P < .001), RFS (log rank, P < .001), and
OS (log rank, P < .001) in overall CRCCs (Figure 3A). The PD1+/high
Treg subgroup showed shorter DMR, RFS, and OS duration and the
PD1−/low Treg subgroup had longest DMR, RFS, and OS duration.
The 10-year survival rates of the PD1−/low Treg, PD1+/low Treg
or PD1−/high Treg, and PD1+/high Treg groups were 98%, 75%,
and 53%, respectively. The PD1−/low Treg subgroup had only 1 of
72 patients (1%) with DMR. In contrast, 3 of 57 PD1+/low Treg or
PD1−/high Treg subgroups (5%) and 15 of 70 of the PD1+/high Treg
subgroup (21%) showed DMR. When additional analysis was per-
formed on the separation of CRCC patents according to TNM stage
(stage I versus stages II, III, and IV), there were no patients experienc-
ing DMR in the stage I PD1−/low Treg subgroup and there were no
dead patients in the high stage (stages II–IV) PD1−/low Treg subgroup
(Figure 3, B and C ).
The Infiltration of PD1-Positive Cells and FoxP3-Positive
Tregs in CRCCs Are Independent Prognostic Factors for Worse
Survival Outcomes according to Multivariate Analysis
Multivariate analysis was performed using all patients with complete
information for all variables. All of the variables significantly associ-
ated with DMR, RFS, or OS by univariate analyses were included
Table 1. Clinicopathologic Variables, Intratumoral Infiltration of PD1-Positive Lymphocytes and
FoxP3-Positive Tregs, and EBV Infection in CRCC.
Characteristics n PD1 Treg Score EBV
Positive P High P Positive P
Sex
Male 140 67 (48%) .042 87 (62%) .005 51 (36%) .204
Female 59 19 (32%) 24 (41%) 16 (27%)
Age, years
<55 76 31 (41%) .587 43 (57%) .858 31 (41%) .095
≥55 123 55 (45%) 68 (55%) 36 (29%)
TNM stage
I 162 62 (38%) .003 85 (52%) .049 53 (33%) .552
II to IV 37 24 (65%) 26 (70%) 14 (38%)
LN metastasis
Absence 197 84 (43%) .103 109 (55%) .206 66 (34%) .623
Presence 2 2 (100%) 2 (100%) 1 (50%)
DMR
Absence 180 69 (38%) <.001 96 (53%) .009 60 (33%) .758
Presence 19 17 (89%) 16 (84%) 7 (37%)
Nuclear grade
1 44 7 (16%) <.001 22 (50%) .198 13 (30%) .545
2 117 53 (45%) 63 (54%) 43 (37%)
3 and 4 38 26 (68%) 26 (68%) 11 (29%)
Necrosis
Absence 172 71 (41%) .164 91 (53%) .04 53 (31%) .032
Presence 27 16 (56%) 20 (74%) 14 (52%)
EBV
Negative 132 56 (42%) .752 71 (54%) .427
Positive 67 30 (45%) 40 (60%)
Treg
Low 88 16 (18%) <.001
High 111 70 (63%)
Treg, FoxP3-positive regulatory T cells.
Table 2. Univariate Cox Regression Analysis for OS, RFS, and DMR in CRCC Patients.
Characteristics n DMR, HR (95% CI) P RFS, HR (95% CI) P OS, HR (95% CI) P
Sex, male (vs female) 140 0.261 (0.060–1.131) .073 0.416 (0.174–0.995) .049 1.954 (0.743–5.141) .175
Age, years, ≥55 (vs <55) 123 1.960 (0.705–5.453) .197 2.309 (1.092–4.882) .029 3.245 (1.233–8.540) .017
TNM stage, II to IV (vs I) 37 10.938 (4.151–28.823) <.001 5.591 (2.955–10.577) <.001 3.750 (1.762–7.889) <.001
LN metastasis, presence (vs absence) 2 25.896 (2.981–224.953) .003 35.949 (7.375–175.220) <.001 3.374 (0.454–25.095) .235
Nuclear grade
1 44 1 .092 1 .001 1 .013
2 117 30878 (0–2 × 1086) .914 6.907 (0.928–51.407) .059 4.617 (0.608–35.049) .139
3 and 4 38 85638 (0–6 × 1086) .906 17.767 (2.354–134.614) .005 11.291 (1.453–87.734) .020
Necrosis, presence (vs absence) 27 1.796 (0.594–5.435) .300 1.853 (0.848–4.049) .122 2.470 (1.048–5.820) .039
EBV positive (vs negative) 67 1.059 (0.414–2.709) .904 1.664 (0.877–3.156) .119 2.792 (1.305–5.977) .008
Treg, high (vs low) 111 5.776 (1.677–19.895) .005 5.708 (2.381–13.687) <.001 6.218 (2.151–17.971) .001
PD1, positive (vs negative) 86 12.371 (2.855–53.608) .001 9.562 (3.729–24.518) <.001 10.802 (3.259–35.806) <.001
Treg, FoxP3-positive regulatory T cell.
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in multivariate analysis. TNM stage and the PD1-positive subgroup
were independent prognostic indicators of DMR and RFS for CRCC
patients. EBV infection and intratumoral infiltration of Tregs or PD1-
positive cells were all independent prognostic indicators of OS of CRCC
patients (Table 3). The patients having tumors with infiltrations of
PD1-positive cells had a 6.146-fold (95% CI, 1.249–30.238) greater
risk of DMR (P = .026), a 5.618-fold (95%CI, 2.028–15.560) decrease
in RFS (P = .001), and a 6.275-fold (95% CI, 1.813–21.715) decrease
in OS (P = .004). The patients with high intratumoral Treg infiltration
had a 3.195-fold (95%CI, 1.046–9.761) decrease inOS (P = .042). The
HR forOSwas 3.671-fold (95%CI, 1.691–7.966) greater in the EBER-
positive patients than EBER-negative patients (P = .001; Table 3).
Discussion
In this study, we have examined the impact of tumor-infiltrating PD1-
positive lymphocytes and Tregs and EBV infection for the prediction of
metastatic potential and prognosis of CRCC. The infiltration of PD1-
positive lymphocytes was an independent indicator of DMR, RFS,
and OS of CRCC. This result suggests that intratumoral infiltration
of PD1-positive lymphocytes could be used as a prognostic indicator
for CRCC patients and helpful for the prediction of latent distant
metastasis of CRCCs. Recent preliminary data from clinical trials with
anti-PD1 antibody for the treatment refractory metastatic CRCC
showed partial responses in 5 of 16 patients and stable disease state
in 3 of 16 patients [13]. In another report, immunotherapy with
anti-PD1 antibody showed response rates of 27% (9 of 33) in RCC,
18% (14 of 76) in non–small cell lung cancer, and 28% (26 of 94) in
melanoma [12]. Therefore, PD1-targeted immunotherapy could po-
tentially be applied to RCC patients, and there is a need to establish a
reliable method for the selection of RCC patients who would be suitable
candidates for PD1-targeted immunotherapy in the practical pathologic
diagnostic field. Although we performed PD1 staining on paraffin-
embedded tissue, our results are consistent with a previous report on
the staining performed on frozen tissue [11]. The presence of the infil-
tration of PD1-positive lymphocytes significantly associated with high
Treg numbers and poor prognostic indicators of CRCC such as higher
TNM stage and histologic nuclear grade. Especially, PD1 positivity
was helpful for the prediction of DMR, even for stage I CRCC. There
was no DMR in 100 PD1-negative stage I patients; however, 6 of
62 PD1-positive stage I RCC patients showedDMR (P = .002). There-
fore, in addition to the prognostic impact of PD1 positivity for CRCC,
our findings suggest that PD1 immunostaining of paraffin-embedded
tissue is also available for the evaluation of the infiltration of PD1-
positive cells in tumors as possible criterion for selection of patients
suitable for PD1-based immunotherapy.
In our study, the high Treg subgroup was also significantly associ-
ated with higher TNM stage, DMR, and tumor necrosis. Moreover,
Figure 2. Kaplan-Meier survival analysis of RCC. (A–F) OS and RFS according to TNM stage (A), nuclear grade of tumor cells (B), histologic
tumor necrosis (C), intratumoral infiltration of PD1-positive cells (D) and FoxP3-positive Tregs (E), and EBV infection (F) in CRCC patients.
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high numbers of Tregs predicted shorter DMR, RFS, and OS for
CRCC. In line with our study, high intratumoral Treg counts are
related to poor prognosis of various human malignant tumors [17,20–
22]. Peripheral blood of RCC patients showed higher numbers of Treg
than that of healthy individuals [20]. Elevated Treg distribution in hu-
man malignant tumors was reduced to normal levels after curative resec-
tions of the tumor [34]. This suggests that some tumor-related factor
could be involved in the expansion of Treg. However, exact mechanism(s)
of how Tregs are involved in the modulation of the tumor micro-
environment is not clear. Possibly, Treg-related immunosuppressive
function could be mediated by blocking the function of T cells and
antigen-presenting cells.
The expression of PD1 has been observed on activated T cells,
especially in the cytoplasm of Treg [35]. In addition, up-regulation
of PD1 on tumor-infiltrating Treg was related with enhanced sup-
pressive function of Treg [7]. Therefore, we also evaluated the impact
of the intratumoral infiltration of Treg and their association with
PD1 positivity. The infiltration of Treg was significantly correlated
with the infiltration of PD1-positive cells. Eighty-one percent of pa-
tients with tumors with infiltration of PD1-positive lymphocytes were
Figure 3. Kaplan-Meier analysis according to the combined intratumoral infiltration patterns of PD1-positive lymphocytes and FoxP3-
positive Tregs in CRCC. (A–C) DMR, RFS, and OS in overall CRCC (A), stage I CRCC (B), and high stage (stages II–IV) CRCC (C).
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also in the high Treg subgroup. The number of PD1-positive lympho-
cytes in low Treg and high Treg subgroups were 2 ± 6 and 31 ± 59,
respectively (P < .001). These results suggest that PD1 and Treg-
mediated immunosuppression contribute to the aggressive progression
CRCC. In line with our results, the high frequency of PD1-positive
T cells in metastatic LNs of papillary thyroid carcinomas and the
positive correlation with Treg infiltration have been reported recently
[36]. In addition, during interleukin-2–based immunotherapy in pa-
tients with metastatic RCC, intratumoral Treg increased and was cor-
related with poor prognosis [16]. In this aspect, this result supports
the hypothesis that PD1 functions as a negative regulator of antitumor
immune responses and that blockage of PD1 and the function of Treg
could be a good stratagem for the immune therapy of CRCC. There-
fore, the evaluation of the infiltration of PD-positive cells or Tregs in
CRCC may be useful for the discrimination of CRCC cases with poor
prognoses, a group that could be candidate for PD1- or Treg-based
additional immunotherapy.
EBV infection occurs in early life for most of the human population
and causes only mild disease. However, after remission, EBV remains
in infected individuals for their lifetime [23,37,38]. When there are
functional deficiencies in T-lymphocyte response, EBV infection could
induce fatal lymphoproliferative disease and is involved in several types
of human malignant tumors. However, there were very limited reports
on the role and prevalence of EBV in RCCs [24,25]. In this study, we
have demonstrated for the first time that EBV infection was signifi-
cantly associated with poor survival of CRCC patients. EBV infection
was an independent prognostic indicator of OS of CRCC patients.
The prevalence of EBV infection in our CRCC group was 34% (67
of 199). This incidence of EBV infection in CRCC is relatively high.
However, most of the EBER staining occurred in the cytoplasm of
tumor cells (48 of 199, 24%) and inflammatory cells (39 of 199,
20%). Nuclear expression of EBER in tumor cells presented in only
six cases of CRCC (3%). Even in these six cases, nuclear expression of
EBER was seen in only one or two tumor cells in 3-mm tissue cores.
We thought that the localization patterns of EBV may be explained by
the fact that the kidney is a reservoir of EBV infection [39,40] and/or
EBV has a possible tumorigenic role in CRCC. Therefore, we per-
formed separate analyses according to the localization of EBV infec-
tion. When we did survival analysis in cases with EBER expression
in tumor cells, regardless of whether EBER staining was nuclear or
cytoplasmic, it did not predict OS (log rank, P = .114). In addition,
there were no clinicopathologic factors associated with EBV infection.
Therefore, we presumed that EBV infection itself did not contribute
to the development of tumor cells in CRCC. However, when addi-
tional analysis was performed with RCC having EBER expression in
inflammatory cells, the EBV infection of inflammatory cells predicted
shorter OS (log rank, P = .005) and RFS (log rank, P = .036). In ad-
dition, the subgroup having EBV infection only in the inflammatory
cells possibly correlated with intratumoral infiltration of Treg (P =
.059). Although the relationship between EBV infection and Treg in-
filtration is still unclear, our findings suggest the possible relationship
between EBV infection and a tumor-permissive immune environment
involving Treg infiltration.
In conclusion, this study has shown that intratumoral infiltration of
PD1-positive or FoxP3-positive lymphocytes was a poor prognostic
indicator of CRCC and predicted poor survival. Especially, PD1 or
FoxP3 positivity was very helpful for the prediction of latent distant
metastasis of CRCCs. Even in stage I CRCCs, PD1 or FoxP3 positivity
predicted DMR, RFS, and OS. Therefore, this study suggests that the
evaluation of the infiltration of PD1-positive lymphocytes or FoxP3-
positive Tregs in CRCC is helpful for the prediction of prognosis
of CRCC patients and for the selection of the patients who could be
suitable for PD1- or Treg-based immunotherapy in the practical
pathologic diagnostic fields.
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